Coformer selection in pharmaceutical cocrystal development: A case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics

Journal of Pharmaceutical Sciences

Volumn 100, Issue 6, 2011, Pages 2172-2181

  Cheney, Miranda L ^a,b   Weyna, David R ^a,b   Shan, Ning ^a   Hanna, Mazen ^a   Wojtas, Lukasz ^b   Zaworotko, Michael J ^b  

^a Thar Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cocrystal; Pharmacokinetics; Solubility

Indexed keywords

ACETYLSALICYLIC ACID; MELOXICAM; MELOXICAM ASPIRIN COCRYSTAL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CRYSTAL; CRYSTALLIZATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SOLUBILITY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHYSICAL CHEMISTRY; PKA; RAT; SINGLE DRUG DOSE;

EID: 79954476664     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22434     Document Type: Article

References (51)

1. Allen LV, Popovich NG, Ansel HC. 2005. Ansel's pharmaceutical dosage forms and drug delivery systems. Baltimore, Maryland: Lippincott Williams and Wilkins.
2. Haleblian J, McCrone W. 1969. Pharmaceutical applications of polymorphism. J Pharm Sci 58:911-929.
3. Berge SM, Bighley LD, Monkhous DC. 1977. Pharmaceutical salts. J Pharm Sci 66:1-19.
4. Vishweshwar P, McMahon JA, Bis JA, Zaworotko MJ. 2006. Pharmaceutical co-crystals. J Pharm Sci 95:499-516.
5. Schultheiss N, Newman A. 2009. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des 9:2950-2967.
6. Shan N, Zaworotko MJ. 2008. The role of cocrystals in pharmaceutical science. Drug Discovery Today 13:440-446.
7. Aakeröy CB, Forbes S, Desper J. 2009. Using cocrystals to systematically modulate aqueous solubility and melting behavior of an anticancer drug. J Am Chem Soc 131:17048-17049.
8. Childs SL, Chyall LJ, Dunlap JT, Smolenskaya VN, Stahly BC, Stahly GP. 2004. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J Am Chem Soc 126:13335-13342.
9. Remenar JF, Morissette SL, Peterson ML, Moulton B, MacPhee JM, Guzman HR, Almarsson Ö. 2003. Crystal engineering of novel cocrystals of a triazole drug with 1, 4-dicarboxylic acids. J Am Chem Soc 125:8456-8457.
10. Almarsson Ö, Zaworotko MJ. 2004. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improve medicines? Chem Commun 1889-1896.
11. Remenar JF, Peterson ML, Stephens PW, Zhang Z, Zimenkov Y, Hickey MB. 2007. Celecoxib:Nicotinamide dissociation: using excipients to capture the cocrystal's potential. Mol Pharm 4:386-400.
12. Good DJ, Rodriguez-Hornedo N. 2009. Solubility advantage of pharmaceutical cocrystals. Cryst Growth Des 9:2252-2264.
13. Karki S, Friščić T, Fabian L, Laity PR, Day GM, Jones W. 2009. Improving mechanical properties of crystalline solids by cocrystal formation: new compressible forms of paracetamol. Adv Mater 21:3905-3909.
14. Trask AV, Motherwell WDS, Jones W. 2005. Pharmaceutical cocrystallization: engineering a remedy for caffeine hydration. Cryst Growth Des 5:1013-1021.
15. McNamara DP, Childs SL, Giordano J, Iarriccio A, Cassidy J, Shet MS, Mannion R, O'Donnell E, Park A. 2006. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm Res 23:1888-1897.
16. Lipinski CA. 2000. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235-249.
17. Cheney ML, Shan N, Healey ER, Hanna M, Wojtas L, Zaworotko MJ, Sava V, Song S, Sanchez-Ramos JR. 2010. Effects of crystal form on solubility and pharmacokinetics: a crystal engineering case study of lamotrigine. Cryst Growth Des 10:394-405.
18. Shan N, Zaworotko M. 2010. Polymorphic crystal forms and cocrystals in drug delivery (crystal engineering). In Burger's Medicinal Chemistry and Drug Discovery, p 187-218.
19. Desiraju GR. 1995. Supramolecular synthons in crystal engineering - a new organic-synthesis. Angewandte Chemie 34:2311-2327.
20. Desiraju GR. 1989. Crystal Eng.
21. Allen FH. 2002. The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta Crystallogr Sect B-Struct Sci 58:380-388.
22. Stanton MK, Bak A. 2008. Physicochemical properties of pharmaceutical co-crystals: a case study of ten AMG 517 co-crystals. Cryst Growth Des 8:3856-3862.
23. Mobic® FDA Summary Basis of Approval (NDA # 020938).
24. Luger P, Daneck K, Engel W, Trummlitz G, Wagner K. 1996. Structure and physicochemical properties of meloxicam, a new NSAID. Eur J Pharm Sci 4:175-187.
25. Ghorab MM, Abdel-Salam HM, El-Sayad MA, Mekhel MM. 2004. Tablet formulation containing meloxicam and beta-cyclodextrin: mechanical characterization and bioavailability evaluation. AAPS PharmSciTech 5:59.
26. Takagi T, Ramachandran C, Bermejo M, Yamashita S, Yu LX, Amidon GL. 2006. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm 3:631-643.
27. Auvinet B, Ziller R, Appelboom T, Velicitat P. 1995. Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients with acute sciatica. Clin Ther 17:1078-1090.
28. Han HK, Choi HK. 2007. Improving absorption of meloxicam via salt formation with ethanolamines. Eur J Pharm Biopharm 65:99-103.
29. Ki HM, Choi HK. 2007. The effect of meloxicam/ethanolamine salt formation on percutaneous absorption of meloxicam. Arch Pharm Res 30:215-221.
30. Mezei T, Mesterhazy N, Bako T, Porcs-Makkay M, Gyula S, Balazs V. 2009. Manufacture of high-purity meloxicam via its novel potassium salt monohydrate. Organic Process Res Dev 13:567-572.
31. Rao KP, Saran TSV, Shivappa NN, Shulamite A, Sachin K, Hiremath VA. 2009. Studies on meloxicam microcrystals for improving drug therapy. Indian J Pharm Sci 71:167-168.
32. Childs SL, Rodriguez-Hornedo N, Reddy LS, Jayasankar A, Maheshwari C, McCausland L, Shipplett R, Stahly BC. 2008. Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine. Cryst Eng Comm 10:856-864.
33. Friščić T, Jones W. 2009. Recent advances in understanding the mechanism of cocrystal formation via grinding Cryst Growth Des 9:1621-1637.
34. Bruker SMART, SAINT-Plus, SADABS, XP and SHELXTL. 1997. Madison, Wisconsin.
35. Sheldrick GM. 1997. SHELXTL. Gottingen, Germany: University of Gottingen.
36. Castel-Branco MM, Almeida AM, Falcao AC, Macedo TA, Caramona MM, Lopez FG. 2001. Lamotrigine analysis in blood and brain by high-performance liquid chromatography. J Chromatogr B 755:119-127.
37. Fabiola GF, Pattabhi V, Manjunatha SG, Rao GV, Nagarajan K. 1998. 4-Hydroxy-2-methyl-N-(5-methyl-1, 3-thiazol-2-yl)-2H-1, 2-benzothiazine-3-carboxamide 1, 1-dioxide. Acta Crystallogr Sect C 54:2001-2003.
38. Childs SL, Hardcastle KI. 2007. Cocrystals of piroxicam with carboxylic acids. Cryst Growth Des 7:1291-1304.
39. The range for the hydrogen bond was determined for each search by manual examination of the entries at or near the bottom of the bell curve of the histogram. All entries outside of the defined distance range were excluded.
40. CSD version 5.31, November2009 release including May 2010 update. Search parameters: Organics only, 3D coordinates determined, R < 7.5%.
41. The AUC increase of meloxicam by its coadministration with aspirin could also be the result of GI physiological effects. Further investigation is required to validate this hypothesis.
42. Bhogala BR, Basavoju S, Nangia A. 2005. Tape and layer structures in cocrystals of some di- and tricarboxylic acids with 4, 4'-bipyridines and isonicotinamide. Cryst Eng Comm 7:551-562.
43. Delori A, Suresh E, Pedireddi VR. 2008. pKa-directed host-guest assemblies: rational analysis of molecular adducts of 2, 4-diamino-6-methyl-1, 3, 5-triazine with various aliphatic dicarboxylic acids. Chem-Eur J 14:6967-6977.
44. Mohamed S, Tocher DA, Vickers M, Karamertzanis PG, Price SL. 2009. Salts or cocrystals? A new series of crystal structures formed from simple pyridines and carboxylic acids. Cryst Growth Des 9:2881-2889.
45. Stahl PH, Wermuth CG. 2002. Handbook of pharmaceutical salts: Properties, selection, and use. Zurich, Switzerland: WILEY-VCH.
46. Childs SL, Stahly GP, Park A. 2007. The salt-cocrystal continuum: the influence of crystal structure on ionization state. Mol Pharm 4:323-338.
47. Cheney ML, Weyna DR, Shan N, Hanna M, Wojtas L, Zaworotko MJ. 2010. Supramolecular architectures of meloxicam carboxylic acid cocrystals, a crystal engineering case study. Cryst Growth Des 10:4401-4413.
48. All concentration values in this manuscript refer to meloxicam equivalent concentrations.
49. The regular human dose of 325 mg was used for calculation. For further information, see FDA Orange Book.
50. US FDA CDER. 2005. Guidance for Industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers.
51. Busch U, Schmid J, Heinzel G, Schmaus H, Baierl J, Huber C, Roth W. 1998. Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab Dispos 26:576-584.